Hydroxyurea

Zulassung

Hydroxycarbamid findet Anwendung zur zytoreduktiven Therapie bei myeloproliferativen Erkrankungen
PVSG phase II trial

in order to maintain a platelet count <600,000/microL and the hematocrit below 50 percent, using minimal phlebotomy treatment

Wirkmechanismus

Die Wirkung der Substanz beruht auf der Hemmung des Enzyms Ribonukleotidreduktase, welche die Ribose zur Desoxyribose reduziert. Die DNA-Synthesekapazität der jeweiligen Zelle deutlich eingeschränkt wird

Dosierung

HU, 30 mg/kg per day for one week, followed by 15 mg/kg per day

Wirkung

In a series of 261 patients with PV treated with hydroxyurea for a median time of 4.4 years, complete, partial, and nonresponses were noted in 24, 66, and 10 percent, respectively [122]. However, fulfilling the initial ELN criteria for complete or partial response was not associated with a benefit in the clinical outcome in PV, whereas response in platelet and white blood cell counts were predictive of less thrombohemorrhagic complications and better prognosis, respectively [120]. Resistance to treatment with hydroxyurea was an adverse prognostic factor, with a significantly higher risk of both death and disease transformation.

Nierenfunktion

 

 

Leberfunktion

 

Behandlungsende

 

Infektionen

 

sonstige NW

 

Absetzreaktion